          |
|
J. Gordon Foulkes, Ph.D., Managing Director Gordon Foulkes joined RiverVest in August 2005 as a venture partner and is now a managing director. He has more than 25 years of experience in biopharmaceutical research and development. Prior to joining RiverVest, Dr. Foulkes headed research and development at three biotechnology companies: Oncogene Science, Inc. (now OSI Pharmaceuticals, NASDAQ: OSIP), Aurora Biosciences Corporation (acquired by Vertex), and Elitra Pharmaceuticals (acquired by Merck). At OSI, he pioneered the early development of cell based high-thoroughput drug screening and oversaw multiple drug discovery programs, moving several from gene discovery to clinical trials. The most advance of these programs is Tarceva®, an EGF receptor kinase inhibitor that received FDA approval for treatment of lung cancer in 2004, and subsequently for pancreatic cancer. He has had a lead role in securing more than 15 corporate partnerships, resulting in over $200 million in recognized collaborative revenues and involving a diverse array of therapeutic areas and technology platforms. He has also directly participated in raising over $145 million in private, IPO, and follow-on public offerings. Dr. Foulkes is a board observer for MacroGenics and served as a board observer for Conforma, acquired by Biogen Idec in May 2006, both Fund I companies. Dr. Foulkes has served on the boards of directors of Vitra Bioscience (formerly Virtual Arrays), Aurora Biosciences, Elitra Pharmaceuticals, and OSI Pharmaceuticals. Dr. Foulkes has held academic positions at the Massachusetts Institute of Technology and was a tenured staff member of The Medical Research Council in the United Kingdom. He completed his Ph.D. in 1980 at the University of Dunee, Scotland, under Professor Sir Philip Cohen.J. Gordon Foulkes, Ph.D. |
©2005 RiverVest Venture Management, LLC